58 -11 (49) 2022 — Yuldashev S.Zh., Ibragimova D.N. — CORRECTION OF SLEEP DISTURBANCES IN PARKINSON’S DISEASE USING CIRCAD RATE REGULATOR THERAPY

CORRECTION OF SLEEP DISTURBANCES IN PARKINSON’S DISEASE USING CIRCAD RATE REGULATOR THERAPY

Yuldashev S.Zh., Samarkand Medical University, Uzbekistan

Ibragimova D.N., Samarkand Medical University, Uzbekistan

Shukurova D.B. Samarkand Medical University, Uzbekistan

Resume

This article presents modern and effective principles for the treatment of vascular Parkinsonism and Parkinson’s disease. Today, cognitive changes in vascular parkinsonism and Parkinson’s disease are detected in the late stages of the disease, and treatment begins late, therapy treats sleep disorders in both Parkinson’s disease and secondary vascular parkinsonism, and also has a positive effect on the therapy of the disease, improves the quality of life of patients and provides convenience for the relatives of the patients.

Key words: Parkinson’s disease, vascular Parkinsonism, circadian arrhythmias, insomnia, parasomnia, hypersomnia, circadian rhythm regulators.

First page

318

Last page

322

For citation: Yuldashev S.Zh., Ibragimova D.N.Shukurova D.B. – CORRECTION OF SLEEP DISTURBANCES IN PARKINSON’S DISEASE USING CIRCAD RATE REGULATOR THERAPY //New Day in Medicine 11(49)2022 318-322 https://clck.ru/32nYAC

LIST OF REFERENCES:

1. Beine B. Neurophysiologic basis of sleep and walkefulness. In: Fundamentals of sleep technology. N. Butkov, T. Lee-Choing (eds). // Philadelphia: LWW, 2007; 11–7.
2. Bordet R., Devos D., Brique S. et al. Study of circadian melatonine secretion pattern at different stages of Parkinsons disease. // Clin Neuropharmacol 2003; 26(2):65–72.
3. Fertl E., Auff E., Doppelbauer A., Waldhauser F. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa. // J Neural Transm Park Dis Dement Sect 1993;5(3):227–34.
4. Adi N., Mash D.C., Ali E. et al. Melatonin MT1 and MT2 receptors expression in Parkinsons disease. // Med SciMonit 2010; 61–7
5. Ianas O., Olinescu R., Badescu I. Melatonin involvement in oxidative processes. // Еndocrinologie 1991;29(3–      4):147–53.
6. Reiter R.J., Robinson J. Melatonin. New York: Bantam books, 1995.
7. Kaynak D., Kiziltan G., Kaynak H. et al. Sleep and sleepiness in patients with Parkinson’s disease before and after dopaminergic treatment. // Eur J Neurol 2005; 12(3):199–207.
8. Chaudhuri K.R., Pal S., DiMarco A. et al. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. // J NeurolNeurosurg Psychiatry 2002; 73(6):629–35.
9. Johns M.W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540–45
10. Peto V., Jenkinson C., Fitzpatrick R. PDQ39: A review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures. // Neurol 1998; 245(Suppl 1):10–4.
11. Brown R.G., Dittner A., Findley L. et al. The Parkinson fatigue scale. // Park Relat Dis 2005; 11:49–55.
12.  Akramova D., Rakhimbaeva G. Hormonal pathogenetic effects and vascular-immunological aspects in secondary vascular parkinsonism, // Parkinsonism Related Disorders, Volume 46, Supplement 2,January 2018,Page e6
13. Hartmann  A. Veldhuisb M. Deuschlea H. Standhardta He user, Twenty-Four Hour Cortisol Release Profiles in Patients With Alzheimer’s and Parkinson’s Disease Compared to Normal Controls: Ultradian Secretory Pulsatility and Diurnal Variation, // Neurobiology of Aging Volume 18, Issue 3, May–June 1997, Pages 285-289
14. Phillips K., Salmon P., Siwik C., Rebholz W., Cash E., Litvan I., Filoteo J.V., Kayser K., Sephton S.E. A dyadic Mbsr intervention for Parkinson’s disease patients/caregivers: Effects on distress, cortisol, and inflammation, Brain, Behavior, and Immunity, Volume 66, Supplement, November 2017, Pages 19-20